BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 Financial Report, Clinical Studies Update
Feb 12, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 third quarter, ending Dec. 21, 2020. Highlights of the report are the company’s strengthened balance sheet following the closing of its recent underwritten public offering, which resulted in $100 million. In the report, the company also noted that it expects to launch multiple clinical studies during the 2021 calendar year, including crucial Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (“SAD”). Other planned exploratory trials include PH94B Phase 2 studies in adult patients experiencing additional anxiety-related disorder; the company is also planning on completing preparation for the Phase 2B clinical development of its PH10 as a potential rapid-onset standalone treatment for major depressive disorder in early 2022. “Calendar 2020 was transformative, highlighted by closing a PH94B partnership, a positive meeting with the FDA regarding the key aspects of the study design for our upcoming pivotal Phase 3 studies of our PH94B nasal spray in social anxiety disorder and, during the most recent quarter, closing a $100 million financing which involved significant participation from leading healthcare institutional investors such as Acuta Capital, New Enterprise Associates, OrbiMed and Venrock Healthcare Capital Partners, among others,” said VistaGen CEO Shawn Singh in the press release. “We are encouraged by these transformative milestones. Together, they have further advanced our tenacious pursuit to bring life-changing medications to the millions affected by anxiety, depression and other mental health challenges worldwide.”
For view the full press release, visit https://ibn.fm/5C7Pu
About VistaGen Therapeutics Inc.
VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
OpenAI unveils AI assistant 'dots' while safety worries delay new model
Sam Altman spoke in San Francisco during OpenAI’s annual event for tech developers.
Risks being taken with heating oil orders, firm says
Customers in Berkshire and Hampshire are leaving it late to refill their tanks, an oil firm says.
Facing the future without the 'bank of mum and dad'
Young people struggling to make ends meet respond to the government's Your First Home scheme.
Three takeaways from Trump's 'Super Intelligence' summit
The meeting at the White House came as some tech bosses and experts have called for tighter rules around AI.
China says reported European '301' tool typical act of protectionism
China on Tuesday said a reported tool being pushed by some European Union member states is a typical example of protectionism and unilateralism that would disrupt China-EU trade as well as the stability of global industrial and supply chains.
A.I. Is ‘Better Informed’ Than Doctors, Kennedy Tells Industry-Backed MAHA Summit
The health secretary, Vice President JD Vance and other top officials addressed a conference sponsored by corporations, including A.I. companies and others with business before the government.
Chinese AI tool told researchers how to make bioweapons
Mindgard said it discovered in July that Kimi models K2.6 and K3 Swarm could evade developer's safety limits.
The start-ups hoping to return battery making to the US
Batteries based on sodium-ion technology could be made in the US with locally sourced materials.
Huel ad banned for suggesting its products could replace all meals
The advertising watchdog said that viewers could assume from the ad that replacing all normal food with Huel was "nutritionally appropriate".
X2, the Troubled California Six Flags Roller Coaster, Reaches Its End
The ride at Magic Mountain near Los Angeles has fueled lawsuits claiming that it had caused brain injuries, including two that were fatal.
Paramount’s Streaming Chief Leaves Ahead of Warner Bros. Deal
Cindy Holland’s departure clears the way for Casey Bloys, the HBO chairman, to have a leading role in the combined company’s streaming services.
Mideast Oil Exports Rebound Even as Prices Remain Elevated
More tankers are moving through the Strait of Hormuz as shippers gain confidence, but the global supply of oil is still below demand.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.